Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment

被引:53
|
作者
Fujii, Tsutomu [1 ]
Yamada, Suguru [1 ]
Murotani, Kenta [2 ]
Kanda, Mitsuro [1 ]
Sugimoto, Hiroyuki [1 ]
Nakao, Akimasa [1 ]
Kodera, Yasuhiro [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi 4668550, Japan
[2] Aichi Med Univ, Clin Res Ctr, Nagakute, Aichi 48011, Japan
关键词
ADJUVANT CHEMOTHERAPY; DUCTAL ADENOCARCINOMA; CANCER; RESECTION; PANCREATICODUODENECTOMY; CHEMORADIATION; GEMCITABINE; CARCINOMA; TRIAL; JAPAN;
D O I
10.1097/MD.0000000000001647
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Combined arterial resection during pancreatectomy can be a challenging treatment, and outcome would be more favorable if the tumor becomes technically removable from the artery. Neoadjuvant chemoradiotherapy (NACRT) is expected to achieve locoregional control and enable margin-negative resection. To investigate the effects of NACRT in patients with pancreatic adenocarcinoma (PDAC) which were deemed borderline resectable through preoperative imaging due to abutment of the major artery, including the superior mesenteric artery (SMA) or common hepatic artery (CHA), but were still considered to be technically removable. In the current study, comparisons were make between 71 patients who underwent upfront surgery and 21 patients who underwent NACRT followed by surgery in the strategy to preserve the artery, using unmatched and inverse probability of treatment weighting analysis (UMIN000017115). Fifty patients in the upfront surgery group and 18 in the NACRT group underwent curative resection (70% vs 86%, respectively; P=0.16). The results of the propensity score weighted logistic regressions indicated that the incidences of pathological lymph node metastasis and a pathological positive resection margin were significantly lower in the NACRT group (odds ratio, 0.006; P<0.001 and odds ratio, 0.007; P<0.001, respectively). Among the propensity-score matched patients, the estimated 1- and 2-year survival rates in the upfront surgery group were 66.7% and 16.0%, respectively, and those in the NACRT group were 80.0% and 65.2%, respectively. In conclusion, it was suggested that chemoradiotherapy followed by surgery provided clinical benefits in patients with PDACs in contact with the SMA or CHA.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Comparisons of postoperative outcomes of laparoscopic versus open surgery using inverse probability of treatment weighting analysis: an evidence from Iran
    Jamali, Zahra
    Pourahmad, Mahboobeh
    Khazraei, Hajar
    Bahrami, Faranak
    Bayati, Mohsen
    Pourahmad, Saeedeh
    BMC SURGERY, 2024, 24 (01)
  • [42] Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma
    Barbetta, Arianna
    Hsu, Meier
    Tan, Kay See
    Stefanova, Dessislava
    Herman, Koby
    Adusumilli, Prasad S.
    Bains, Manjit S.
    Bott, Matthew J.
    Isbell, James M.
    Janjigian, Yelena Y.
    Ku, Geoffrey Y.
    Park, Bernard J.
    Wu, Abraham J.
    Jones, David R.
    Molena, Daniela
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (06): : 2710 - 2719
  • [43] Clinical Outcomes of Intra-arterial Chemoradiotherapy and Neoadjuvant Chemoradiotherapy Followed by Surgery for Maxillary Sinus Squamous Cell Carcinoma
    Yunaiyama, Daisuke
    Tsukahara, Kiyoaki
    Okubo, Mitsuro
    Saito, Kazuhiro
    IRANIAN JOURNAL OF RADIOLOGY, 2021, 18 (03)
  • [44] Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro- oesophageal junction
    Faron, Matthieu
    Cheugoua-Zanetsie, Armel Maurice
    Thirion, Pierre
    Nankivell, Matthew
    Winter, Kathryn
    Cunningham, David
    Van der Gaast, Ate
    Law, Simon
    Langley, Ruth
    de Vathaire, Florent
    Valmasoni, Michele
    Mauer, Muriel
    Roth, Jack
    Gebski, Val
    Burmeister, Bryan H.
    Paoletti, Xavier
    van Sandick, Johanna
    Fu, Jianhua
    Ducreux, Michel
    Blanchard, Pierre
    Tierney, Jayne
    Pignon, Jean-Pierre
    Michiels, Stefan
    EUROPEAN JOURNAL OF CANCER, 2021, 157 : 278 - 290
  • [45] The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study
    Su, Yung-Yeh
    Chao, Ying-Jui
    Wang, Chih-Jung
    Liao, Ting-Kai
    Su, Ping-Jui
    Huang, Chien-Jui
    Chiang, Nai-Jung
    Yu, Yu-Ting
    Tsai, Hong-Ming
    Chen, Li-Tzong
    Shan, Yan-Shen
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (09) : 2614 - 2623
  • [46] Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by radical surgery for locally advanced oesophageal squamous cell carcinoma: meta-analysis
    Kamarajah, Sivesh K.
    Evans, Richard P. T.
    Griffiths, Ewen A.
    Gossage, James A.
    Pucher, Philip H.
    BJS OPEN, 2022, 6 (06):
  • [47] Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity-Modulated Radiotherapy Versus Upfront Surgery for Resectable Pancreatic Cancer: A Retrospective Cohort Study
    Yamane, Kei
    Anazawa, Takayuki
    Nagai, Kazuyuki
    Kasai, Yosuke
    Masui, Toshihiko
    Izuwa, Aya
    Kurahashi, Koki
    Ishida, Satoshi
    Ogiso, Satoshi
    Yoshimura, Michio
    Iwai, Takahiro
    Matsubara, Junichi
    Fukuda, Akihisa
    Isoda, Hiroyoshi
    Hidaka, Yu
    Ibi, Yumiko
    Hatano, Etsuro
    ANNALS OF SURGICAL ONCOLOGY, 2025, : 3603 - 3613
  • [48] Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS)
    Van Heijl M.
    Van Lanschot J.J.B.
    Koppert L.B.
    Van Berge Henegouwen M.I.
    Muller K.
    Steyerberg E.W.
    Van Dekken H.
    Wijnhoven B.P.L.
    Tilanus H.W.
    Richel D.J.
    Busch O.R.C.
    Bartelsman J.F.
    Koning C.C.E.
    Offerhaus G.J.
    Van Der Gaast A.
    BMC Surgery, 8 (1)
  • [49] Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial
    Versteijne, Eva
    van Dam, Jacob L.
    Suker, Mustafa
    Janssen, Quisette P.
    Groothuis, Karin
    Akkermans-Vogelaar, Janine M.
    Besselink, Marc G.
    Bonsing, Bert A.
    Buijsen, Jeroen
    Busch, Olivier R.
    Creemers, Geert-Jan M.
    van Dam, Ronald M.
    Eskens, Ferry A. L. M.
    Festen, Sebastiaan
    de Groot, Jan Willem B.
    Koerkamp, Bas Groot
    de Hingh, Ignace H.
    Homs, Marjolein Y., V
    van Hooft, Jeanin E.
    Kerver, Emile D.
    Luelmo, Saskia A. C.
    Neelis, Karen J.
    Nuyttens, Joost
    Paardekooper, Gabriel M. R. M.
    Patijn, Gijs A.
    van der Sangen, Maurice J. C.
    de Vos-Geelen, Judith
    Wilmink, Johanna W.
    Zwinderman, Aeilko H.
    Punt, Cornelis J.
    van Tienhoven, Geertjan
    van Eijck, Casper H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (11) : 1220 - +
  • [50] Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
    Bradley, Alison
    Van Der Meer, Robert
    SCIENTIFIC REPORTS, 2019, 9 (1)